Quick Answer
Lexeo Therapeutics, Inc. reported Stockholders Equity of $246.67 million for the year ending 2025.
- Lexeo Therapeutics, Inc. showed an increase of +111.1% in Stockholders Equity from 2024 to 2025.
- This data is from Lexeo Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2022: -$67.83 million | Q2 2022: -$82.42 million | Q3 2022: -$98.98 million | Q1 2023: -$131.18 million | Q2 2023: -$143.62 million | Q3 2023: -$162.81 million | Q1 2024: $182.95 million | Q2 2024: $164.95 million | Q3 2024: $139.33 million | Q1 2025: $88.12 million | Q2 2025: $138.22 million | Q3 2025: $120.83 million.
- Over the full 5 years of available data (2021 to 2025), Lexeo Therapeutics, Inc.'s Stockholders Equity has grown by 543.6%.
- Historical annual values: Fiscal year 2025: $246.67 million | Fiscal year 2024: $116.84 million | Fiscal year 2023: $113.54 million | Fiscal year 2022: -$112.95 million | Fiscal year 2021: -$55.60 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: